Indeed, in the section titled “emerging biomarkers to identify novel therapies for patients with metastatic NSCLC”, they included high-level MET amplification as a genetic alteration (i.e., driver event) and indicated that available targeted agents with activity against driver events in lung cancer are capmatinib, tepotinib, and crizotinib [3,93]. The gene discussed is MET; the disease is lung carcinoma.